Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Oct;46(7):1322-1324.
doi: 10.1111/ced.14715. Epub 2021 Jun 13.

Risankizumab for pityriasis rubra pilaris

E Brocco  1 , E Laffitte  1
Affiliations

Risankizumab for pityriasis rubra pilaris

E Brocco et al. Clin Exp Dermatol. 2021 Oct.
No abstract available

PubMed Disclaimer

References

    1. Feldmeyer L, Mylonas A, Demaria O et al. Interleukin 23-helper T cell 17 axis as a treatment target for pityriasis rubra pilaris. JAMA Dermatol 2017; 153: 304-8.
    1. Matsuda T, Yamazaki F, Ueda-Hayakawa I et al. Case of pityriasis rubra pilaris progressed to generalized erythroderma following blockade of interleukin-17A, but improved after blockade of interleukin-12/23 p40. J Dermatol 2019; 46: 70-2.
    1. Pilz AC, Seiringer P, Biedermann T et al. Treatment of pityriasis rubra pilaris with guselkumab. JAMA Dermatol 2019; 155: 1424-6.
    1. Huang YW, Tsai TF. A drug safety evaluation of risankizumab for psoriasis. Expert Opin Drug Saf 2020; 19: 395-402.
    1. Crowley JJ, Warren RB, Cather JC. Safety of selective IL-23p19 inhibitors for the treatment of psoriasis. J Eur Acad Dermatol Venereol 2019; 33: 1676-84.

MeSH terms

LinkOut - more resources